ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
B02BD08 | BioTech | Eptacog alfa (activated) recombinant - 1mg | 5540/388 | 218019/09 | NOVOSEVEN RT | 1mg (50KIU) | 1 | Injectable powder for solution+diluent | IV | Mersaco | Novo Nordisk AS | Denmark | L.L | 10.71 | E1 | Novo Nordisk AS | Denmark | 2/5/2024 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
B02BD08 | BioTech | Eptacog alfa - 1mg | 10083 | 139519/1 | ARYOSEVEN RT | 1mg | 1 | Injectable powder for solution+diluent | IV | Lebiran SARL | Aryogen Pharmed | Iran | 16,902,713 L.L | 19.35 | D | Aryogen Pharmed | Iran | 2/5/2024 | 0 |
B02BD08 | BioTech | Eptacog alfa (activated) recombinant - 1mg | 5540 | 218019/09 | NOVOSEVEN RT | 1mg (50KIU) | 1 | Injectable powder for solution+diluent | IV | Mersaco | Novo Nordisk AS | Denmark | 56,263,955 L.L | 10.71 | E1 | Novo Nordisk AS | Denmark | 2/5/2024 | 0 |
B02BD08 | BioTech | Eptacog alfa - 1mg | 10083/388 | 139519/1 | ARYOSEVEN RT | 1mg | 1 | Injectable powder for solution+diluent | IV | Lebiran SARL | Aryogen Pharmed | Iran | L.L | 19.35 | D | Aryogen Pharmed | Iran | 2/5/2024 |